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Abstract
Background: Data on outcome of ERA is scarce and there is lack of well-accepted tools. JADI is
a newly described outcome measure in JIA that has not been evaluated in ERA. We studied
outcome in ERA using JADI and correlated it with traditional outcome measures.
Methods: We studied 49 consecutive patients of ERA with age ≥ 5 years and duration ≥ 1 year.
Along with JADI, we recorded enthesitis, lumbar spinal anterior flexion by modified Schober's
method, presence of inflammatory backache, loss of school years, HAQ-S, growth and pubertal
delay. Parent's/patient's and physician's global assessments on 100 mm visual analogue scale.
Results: The median age was 18.0 (10–27) years and the median duration of disease was 6.0 (1–
17) years. All the patients were male and half (53.1%) were HLA B 27 positive. Fourteen had
decreased anterior lumbar flexion movement and 32 had inflammatory backache. Active enthesitis
was present in 63.3%. Functionally, mild, moderate and severe disability was seen in 18.4%, 34.7%
& 14.3% respectively. Sixty five percent of patients lost education years. Twenty-eight patients had
damaged joints with median of 2.0 joints (0–9). Seventeen patients (34.7%) had damaged joints in
JADI-A score with a median of 1.0 (0–12). Growth failure was the commonest extra articular
damage (8.2%) in JADI-E. JADI correlated with HAQ-S, parent's or patient's & physician's global
assessment (p < 0.01). Limitation of spinal mobility had high correlation with HAQ-S; correlation
with JADI-A was low.
Conclusion: Three fourth of the ERA patients had functional limitations. Half of the patients had
damaged joints. Even though JADI correlated well with traditional outcome measures, it
underestimates joint damage, and does not assess enthesitis and spinal limitation which affect
functional status in ERA. Inclusion of these may make it more useful for ERA.
Introduction
Enthesitis-related arthritis (ERA), as defined by ILAR crite-
ria [1], is characterized by the involvement of the entheses
and the axial skeleton along with peripheral joints. It is an
HLA B-27 related disease and is similar to traditionally
defined juvenile spondylarthropathy, including juvenile
ankylosing spondylitis (JAS), seronegative enthesopathy
and arthropathy (SEA) syndrome, and undifferentiated
juvenile spondylarthropathy, though there is controversy
regarding use of various terminology [2-5]. Although
adult-onset AS (AoAS) and JAS share many common fea-
tures, JAS is associated with worse functional outcome
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Spinal deformity is also more common in JAS than adult
onset AS [6].
In most outcome studies in Juvenile Idiopathic Arthritis
(JIA), number of patients with ERA is small compared to
other subtypes of JIA. Remission rates in ERA have ranged
from 17% to 37% and the frequency of severe disability
from 4% to 52% [7-11]. In a recently published study
where ILAR criteria was used for case definition, patients
with ERA had lower levels of physical functioning, poorer
physical health, and more bodily pain compared to
patients with oligoarthritis or polyarthritis after a median
disease duration of 15.3 years [12].
There is no universally accepted outcome measure for ERA
patients. Many use development of radiological sacroilii-
tis or ankylosing spondylitis as an outcome measure;
however, radiology is not suitable for as radiological sac-
roilitis may take decades to develop. Radiological indices
developed for other subtypes of JIA do not reflect true
damage in ERA as such indices measure damages in wrists
and knees, whereas in ERA involvement of hip joint and
spine are more common.
Childhood health Assessment Questionnaire (CHAQ) is
the most commonly used tool to assess physical disability
due to disease. CHAQ evaluates physical functions in
dressing, getting up, walking, eating, hygiene, reaching
overhead objects, grip and activities. In ERA, spine is also
involved in contrast to other subtypes of JIA and CHAQ
does not contain items to measure functional limitation
because of spinal involvement. HAQ modified for spond-
yloarthropathy (HAQ-S) has been used to measure func-
tional outcome in young adults with ERA [14,12]. In the
HAQ-S, 5 items forming 2 areas, bending and driving, are
added to the HAQ [14]. HAQ-S has been evaluated in
adult patients with spondyloarthropathy [14].
The Juvenile Arthritis Damage Index (JADI) is a newly
described outcome measure in JIA [13]. It assess overall
articular (JADI-A) and extraarticular damage (JADI-E).
The JADI-A score had high correlation with the number of
joints with limited range of motion and moderate correla-
tion with the childhood HAQ (CHAQ), Steinbrocker
functional classification, and radiographic damage. The
JADI-A also performed well to differentiate different levels
of disability. The patients with ERA were excluded from
this study.
Though according to the western literature 11–16% of
patients with JIA have ERA [2-5,12], in India it is probably
the commonest subtype of JIA seen by rheumatologists
[15]. Data on outcome of ERA patients from India are
scarce. Therefore, we studied the outcome of ERA subtypes
with both traditional outcome measures and JADI and
observed whether JADI correlate with traditional meas-
ures or not.
Materials and methods
The study population consisted of 49 consecutive patients
with ERA who attended the outpatient clinic at a tertiary
care referral hospital. ERA was defined according to the
ILAR criteria [1]: onset of arthritis before the 16th birth-
day and persisting for at least 6 weeks; arthritis and
enthesitis, or arthritis or enthesitis with at least 2 of (a)
presence of or a history of sacroiliac joint tenderness and/
or inflammatory lumbosacral pain, (b) presence of HLA-
B27 antigen, (c) onset of arthritis in a male over 6 years of
age, (d) acute (symptomatic) anterior uveitis (e) history of
ankylosing spondylitis, enthesitis related arthritis, sacro-
iliitis with inflammatory bowel disease, Reiter's syn-
drome, or acute anterior uveitis in a first-degree relative
[1]. By definition, patients with psoriasis or a history of
psoriasis in the patient or first-degree relative, presence of
IgM rheumatoid factor and systemic JIA are not included
in ERA subtype [1]. Other inclusion criteria were age more
than 5 years and disease duration of greater than one year.
Same Rheumatologist (PKS) examined all patients. Onset
of symptoms was taken as the date of onset of disease.
JADI scores were calculated as described previously [13].
The index is composed of articular (JADI-A) and extraar-
ticular (JADI-E) damage. In the JADI-A, 36 joints or joint
groups are assessed for the presence of damage: cervical
spine, shoulders, elbows, wrists, individual metcar-
pophalangeal and proximal interphalangeal joints, hips,
and knees; right and left temporomandibular joints, ankle
and subtalar joints and metatarsophalangeal joint of each
foot are considered as a single unit. The damage observed
in each joint is scored as 1 in case of partial damage, or 2
in case of severe damage, ankylosis, or prosthesis. Con-
tractures and other joint deformities are scored when they
are completely explained by prior damage and are not due
to active arthritis and are present for at least 6 months. For
each joint, only the most severe lesions are scored. The
maximum possible JADI-A score is 72.
For JADI-E, muscle atrophy, osteoporosis with fractures or
vertebral collapse, avascular necrosis of bone, significant
abnormality of the vertebral curve due to leg length dis-
crepancy or hip contracture, significant leg length discrep-
ancy or growth abnormality of a bone segment, striae
rubrae, subcutaneous atrophy resulting from intraarticu-
lar corticosteroid injection, growth failure, pubertal delay,
diabetes mellitus and amyloidosis are scored as 1 if
present; ocular complications like cataract or other com-
plications of uveitis were scored as 1 if present, 2 if surgery
was required and 3 in case of legal blindness.Page 2 of 7
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there was edema, anasraca, proteinuria or disproportion-
ately increased ESR. Growth was assessed by plotting
height and weight on standardized Indian pediatric
growth charts. Growth failure was defined as the presence
of two or more of the following: less then 3rd percentile
height for age, growth velocity less than 3rd percentile for
age or crossing at least 2 centile on growth chart [13].
Delayed puberty was defined if no testicular enlargement
occurred by 14 years of age.
Educational level achieved, loss of school years, func-
tional status measured by HAQ-S [14] were also recorded.
For the purposes of analysis, the HAQ-S score was divided
into 4 categories: 0 = no disability, >0 and ≤ 0.5 = mild
disability, >0.5 and ≤1.5 = moderate disability, and > 1.5
= severe disability [13]. Hundred mm Visual Analogue
Scale (VAS) was used for parent/patient's assessment of
their disease.
Examination included physician's global assessment on
100 mm VAS, number of active joints as defined by pres-
ence of swelling (excluding bony swelling) or any two of
limitation of motion (LOM), pain, heat, or tenderness
and number of joints with limited range of motion
(ROM); 67 joints were assessed [13].
Enthesitis was defined as discretely localized tenderness at
the point of insertion of ligaments, tendons, joint cap-
sules, or fascia to bone [12,16]. Anterior lumbar flexion
was assessed using the modified Schober's method
[12,17]. Reduced lumbar flexion was defined as values ≤
6.5 cm in boys and ≤ 5.5 cm in girls [11,18]. Inflamma-
tory back pain was defined as lumbosacral spinal pain at
rest, with morning stiffness that improved with move-
ment [1,12]. Erythrocyte Sedimentation rate (ESR) was
measured by Westergren method. Remission was defined
as described previously [19].
Statistical analysis
We used SPSS (version 13) software for statistical analysis.
Spearman's rank correlation coefficient (rS) was used to
assess correlations among different parameters. Correla-
tions > 0.7 were considered high, 0.4 to 0.7 moderate and
<0.4 low [13,20]. P values less than 0.05 were considered
significant and less than 0.01 as highly significant.
Results
The median age at the time of the study of the 49 patients
with ERA was 18.0 years (range 10–27 years) and the
median duration of disease was 6.0 years (1–17 years). All
the patients were male and median age at disease onset
was 11.0 (6–15) years. Half (53.1%) of the patients were
HLA B 27 positive. Four (8.1%) patients were in remission
at the time of the study. Twenty-eight patients (57.1%)
had joints with limitation of motion with median of 2.0
joints (0–9); the frequency distribution of number of
joints with limitation of motion is shown in table 1. Four-
teen (28.6%) and 32 (65.3%) of the patients had
decreased anterior lumbar flexion movement by modified
Schober's method and inflammatory backache respec-
tively. Active enthesitis was present in 62.59% of the
patients.
At the time of the study, 45 patients were on NSAID;
Indomethacin was the most commonly prescribed
NSAID- 25 patients (51.0%) were on it. Four (8.1%)
patients were on oral steroid, in a dose of 7.5–10 mg daily.
Eighteen patients (37.3%) had received intra-articular
(IA) steroid. Nineteen patients were on DMARDs at the
time of the study; Methotrexate was the commonest
DMARD used (n = 9, 18.3%); 4 (8.3%) patients were on
Salazopyrine. Side effects of drug were seen in 5 patients.
Cytopenia occurred in 3 and GI toxicity in 2.
JADI-A
In JADI-A scoring 17 patients (34.7%) had damaged
joints. JADI-A score varied from 0 – 12 with a median of
1.0. Hip was the commonest damaged joint (n = 14;
28.6%), followed by ankles (7, 14.3%), cervical spine (3,
6.1%), elbows (2, 4.1%) and knees (1, 2.0%). None of the
patients had temporomandibular, shoulder, wrist and
MTP joint damage. Small joints of the hands were dam-
aged in 2 (4.1%) patients. The frequency distribution of
JADI-A score are shown in table 2.
Table 1: Frequency of number of joints with limited range of 
motion (LOM)
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Five (10.2%) patients had extraarticular damage with
JADI-E. Three patients (6.1%) had severe muscular atro-
phy. Four (8.2%) patients had growth failure; pubertal
delay was seen in 2 (4.1%). Secondary amyloidosis was
seen in 1 (2.0%). None of the patients had ocular damage.
Disease activity
Parent's/patient's global assessment on visual analogue
scale (VAS) ranged from 0–100 mm (median 40.0);
median score of physician's global assessment in VAS was
40.0 mm (range 0–90 mm). Correlation between the 2
global assessment was good with rS 0.73 (p < 0.01).
Number of active joints varied from 0–9 (median 2.0).
Duration of EMS ranged from nil to whole day (median
nil) and Median ESR was 48.0 (7–140) mm/hour.
Disability
There was no disability in 32.7% patients, mild disability
in 18.4%, moderate disability in 34.7% and severe disa-
bility in 14.3%. Median HAQ-S was 1.0 (0–3).
Loss of school years
Thirty two (65.3%) patients lost some years of education,
with number of years lost due to disease ranging from 0–
10 (median 1.0) years.
Correlation of JADI with other disease variables
As shown in table 3, JADI correlated with HAQ-S, parent's
or patient's global assessment, physician's global assess-
ment, ESR, and radiological damage with p < 0.01. Corre-
lation with HAQ-S, ESR, Patient's/parent's & physician's
global assessment was modest and with JADI-E low.
HAQ-S had high correlation with limitation of spinal
mobility by modified Schober's method (table 4). Corre-
lation of JADI-A with limitation of spinal mobility was
low. Presence of enthesitis has fair correlation with HAQ-
S (p < 0.01) and JADI-A (0.01) (table 5).
Discussion
Our study shows that more than half of the ERA patients
have articular damage and one tenth have extraarticular
damage at a median duration of disease of 5.0 years. Mod-
erate to severe limitation of function was present in 49.0%
patients. One third of the patients had limitation of move-
ment of lumbar spine. More than 90% patients continued
to have active disease.
More than 60% of our patients lost some years of educa-
tion which is high compared to western literature, though
most of previous studies included all JIA subtypes; only
3% of patients were behind age appropriate grade in a
study from Canada [21]; education level attainment of
adults with JIA was similar to controls in 2 studies from
UK and Finland[22,23]. This could be related to poor
social support system in a resource deficient country.
One third of the patients had damaged joints in JADI-A.
Ours is the first study that has used JADI to assess outcome
in patients with ERA. Hip was the commonest joint dam-
aged in our study followed by knees, ankles and cervical
spine. In contrast, in the previous study wrist, elbow and
the interphalangeal joints were more often involved. This
may be explained by the difference in subtypes of JIA
Table 2: Frequency of juvenile arthritis damage index-articular 
(JADI-A)-score








Table 3: Correlation of JADI-A (2 tailed Spearman's correlation 
coefficient)
Parameter Correlation coefficient (rS)




Parent's/patient's global assessment 0.483**
JADI-E 0.311*
Active joint count 0.278
Duration of disease 0.147
Loss of education 0.1
DMARD use 0.046
Steroid use -0.029
*p < 0.05; ** p < 0.01Page 4 of 7
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patients had oligo articular disease and ERA patients were
excluded from their study [13].
The median JADI-A score in our study is higher compared
to the previous study [13] though the median duration of
disease was comparable (5.0 Vs 7.3 years). This may be
because numbers of patients on DMARD were fewer in
our study as effective DMARD for ERA are limited except
anti TNF which most of our patients cannot afford [24].
As with the previous study [13], JADI had moderate corre-
lation with traditional outcome measures like HAQ-S,
Patient's/parent's & physician's global assessment in our
study. However, half of the patients had functional limi-
tations though only 1/3rd had damage in JADI-A score.
The high degree of functional limitation with low JADI-A
score may be due to under-representation of damage in
lower limb joints in JADI score-midtarsal and subtarsal
joints are not scored and MTP joints are clubbed together,
which are commonly involved joints in ERA. For that rea-
son, though more than half of the patients had damaged
joints when 67 joints were counted in each patient com-
pared to 1/3rd in JADI-A score.
The finding of a relatively high level of functional limi-
taion in ERA is supported by a recent study demonstrating
more functional impairment in juvenile AS than in adult
AS [6]. The HAQ-S indices in our patients tended to be
higher than the indices observed by previous authors
[9,12,23]. The high degree of functional limitation and
articular damage in our patients may also be due to selec-
tion bias as ours is a tertiary care and hospital and more
severe cases may have been included.
Another limitation of application of JADI in ERA is
absence of scoring for spinal involvement. Limitation of
spinal mobility had high correlation with HAQ-S; but its
correlation with JADI-A was modest. Inclusion of limita-
tion of spinal movement in JADI may be helpful to detect
damage in ERA. One third of our patients had limitation
of lumbar spine movement by modified Schober's
method, which is lower than the previous study [12].
Reduced spinal mobility occurs in three fourths of
patients with ERA; half of them experience inflammatory
back pain which is comparable to our study [12].
Table 4: Correlation of limitation of spinal mobility by modified 
Schober's method (2 tailed Spearman's correlation coefficient)
Parameter Correlation coefficient (rS)
Physician's global assessment 0.520**
Hip joint damage 0.437**
Knee joint damage 0.228




Parent's/patient's global assessment 0.476**
JADI-E -0.035
Active joint count 0.304*
Duration of disease 0.095
Loss of education 0.179
*p < 0.05; ** p < 0.01
Table 5: Correlation of presence of enthesitis with other 
measures of disease
Parameter Correlation coefficient (rS)
Physician's global assessment 0.526**
Loss of spinal mobility 0.388**
Hip joint damage 0.313*
Knee joint damage -0.189




Parent's/patient's global assessment 0.409**
JADI-E 0.072
Active joint count 0.425**
Duration of disease 0.027
Loss of education 0.264
*p < 0.05; ** p < 0.01Page 5 of 7
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which is not measured by JADI. Patients with persistent
enthesitis develop severe functional and structural prob-
lems, including various degrees of enthesophytosis [24].
Presence of enthesitis had a highly significant correlation
with HAQ-S in our study; but it had no correlation with
JADI-E.
Other extraarticular damage i.e. JADI-E was uncommon in
our study. Frequency of ophthalmological complication
in ERA are less than other subtypes specially oligoarticular
JIA. Since ERA patients usually have acute anterior uveitis
which seldom leaves significant residua even if recurrent
[25]. Frequency of amyloidosis in our study is comparable
to an earlier study by Pkham et al [26]. For growth failure
most of the previous outcome studies on JIA didn't sepa-
rate subtypes; frequency of 7.8% in our study is compara-
ble to the study by Viola s et al [13].
The remission rate among our patients with ERA was
lower than that reported by other authors [8,12]. The fre-
quency of remission in juvenile spondylarthropathy, has
ranged from 17% to 37% [7,9]. This differences may be
due to different definition of remission in various studies.
The remission criteria used in our study have been evalu-
ated for oligoarthritis and polyarthritis but not for ERA
[19]. Patients needing NSAID were not defined as having
remission in our study; some may argue against it as
patients not needing DMARD may be defined as having in
remission if they otherwise fullfil remission criteria.
Our study has many limitations: numbers of patients are
small, is a cross sectional study, the average disease dura-
tion is only 5 years and lacks radiological outcome
In conclusion, three fourth of the ERA patients have func-
tional limitations. JADI is a useful tool to measure articu-
lar and extraarticular damage in ERA; it has a good
correlation with traditional outcome measures. However,
it underestimate lower limb joint damage and does not
estimate spinal damage as well as enthesitis. Inclusion of
limitation of movement of spine, foot joints and score for
enthesitis in JADI may increase its usefulness in ERA.
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